Cargando…

Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to tackle HCC are based on oral multi-kinase inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Devan, Aswathy R., Kumar, Ayana R., Nair, Bhagyalakshmi, Anto, Nikhil Ponnoor, Muraleedharan, Amitha, Mathew, Bijo, Kim, Hoon, Nath, Lekshmi R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308499/
https://www.ncbi.nlm.nih.gov/pubmed/34358082
http://dx.doi.org/10.3390/ph14070656
_version_ 1783728295723925504
author Devan, Aswathy R.
Kumar, Ayana R.
Nair, Bhagyalakshmi
Anto, Nikhil Ponnoor
Muraleedharan, Amitha
Mathew, Bijo
Kim, Hoon
Nath, Lekshmi R.
author_facet Devan, Aswathy R.
Kumar, Ayana R.
Nair, Bhagyalakshmi
Anto, Nikhil Ponnoor
Muraleedharan, Amitha
Mathew, Bijo
Kim, Hoon
Nath, Lekshmi R.
author_sort Devan, Aswathy R.
collection PubMed
description Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to tackle HCC are based on oral multi-kinase inhibitors like sorafenib; however, the clinical use of the drug is restricted due to the limited survival rate and significant side effects, suggesting the existence of a primary or/and acquired drug-resistance mechanism. Because of this hurdle, HCC patients are forced through incomplete therapy. Although multiple approaches have been employed in parallel to overcome multidrug resistance (MDR), the results are varying with insignificant outcomes. In the past decade, cancer immunotherapy has emerged as a breakthrough approach and has played a critical role in HCC treatment. The liver is the main immune organ of the lymphatic system. Researchers utilize immunotherapy because immune evasion is considered a major reason for rapid HCC progression. Moreover, the immune response can be augmented and sustained, thus preventing cancer relapse over the post-treatment period. In this review, we provide detailed insights into the immunotherapeutic approaches to combat MDR by focusing on HCC, together with challenges in clinical translation.
format Online
Article
Text
id pubmed-8308499
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83084992021-07-25 Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma Devan, Aswathy R. Kumar, Ayana R. Nair, Bhagyalakshmi Anto, Nikhil Ponnoor Muraleedharan, Amitha Mathew, Bijo Kim, Hoon Nath, Lekshmi R. Pharmaceuticals (Basel) Review Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to tackle HCC are based on oral multi-kinase inhibitors like sorafenib; however, the clinical use of the drug is restricted due to the limited survival rate and significant side effects, suggesting the existence of a primary or/and acquired drug-resistance mechanism. Because of this hurdle, HCC patients are forced through incomplete therapy. Although multiple approaches have been employed in parallel to overcome multidrug resistance (MDR), the results are varying with insignificant outcomes. In the past decade, cancer immunotherapy has emerged as a breakthrough approach and has played a critical role in HCC treatment. The liver is the main immune organ of the lymphatic system. Researchers utilize immunotherapy because immune evasion is considered a major reason for rapid HCC progression. Moreover, the immune response can be augmented and sustained, thus preventing cancer relapse over the post-treatment period. In this review, we provide detailed insights into the immunotherapeutic approaches to combat MDR by focusing on HCC, together with challenges in clinical translation. MDPI 2021-07-09 /pmc/articles/PMC8308499/ /pubmed/34358082 http://dx.doi.org/10.3390/ph14070656 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Devan, Aswathy R.
Kumar, Ayana R.
Nair, Bhagyalakshmi
Anto, Nikhil Ponnoor
Muraleedharan, Amitha
Mathew, Bijo
Kim, Hoon
Nath, Lekshmi R.
Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
title Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
title_full Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
title_fullStr Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
title_full_unstemmed Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
title_short Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
title_sort insights into an immunotherapeutic approach to combat multidrug resistance in hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308499/
https://www.ncbi.nlm.nih.gov/pubmed/34358082
http://dx.doi.org/10.3390/ph14070656
work_keys_str_mv AT devanaswathyr insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma
AT kumarayanar insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma
AT nairbhagyalakshmi insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma
AT antonikhilponnoor insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma
AT muraleedharanamitha insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma
AT mathewbijo insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma
AT kimhoon insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma
AT nathlekshmir insightsintoanimmunotherapeuticapproachtocombatmultidrugresistanceinhepatocellularcarcinoma